Baby formula maker Abbott reopens Michigan plant amid shortage

Abbott Nutrition’s baby formula plant in Michigan has officially reopened its doors and restarted production after shuttering nearly four months ago.

Hundreds of workers returned to their posts Saturday morning for the first time since the Sturgis facility closed amid contamination concerns in February following the discovery of a deadly bacteria inside.

The closure and a voluntary recall were among several factors that contributed to a nationwide formula shortage crisis.

It will be roughly another six to eight weeks before the Sturgis plant is back to full capacity, according to Abbott, and product returns to shelves with a real impact on families.

“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” the company, one of the largest makers of formula in the U.S., said in a statement. “We will ramp production as quickly as we can while meeting all requirements. We’re committed to safety and quality and will do everything we can to re-earn the trust parents, caregivers and health care providers have placed in us for 130 years.”

The plant’s reopening comes nearly three weeks after it reached an agreement with the U.S. Food and Drug Administration on a plan to reopen safely.

Abbott said it will first prioritize the production of its specialty and metabolic formulas, like its hypoallergenic EleCare, since those formulas are especially critical for medically vulnerable babies who can’t switch to different brands as easily.

The company said it expects to start releasing some EleCare product “on or about June 20,” adding that it is “working hard to fulfill the steps necessary to restart production of Similac and other formulas and will do so as soon as we can.”